Health & Environmental Research Online (HERO)


Print Feedback Export to File
2283527 
Journal Article 
Evaluation of butyrate induced production of A Mannose-6-phosphorylated therapeutic enzyme using Parallel Bioreactors 
Madhavarao, CN; Agarabi, CD; Wong, L; Müller-Loennies, S; Braulke, T; Khan, M; Anderson, H; Johnson, GR 
In Press 
Yes 
Biotechnology and Applied Biochemistry
ISSN: 0885-4513
EISSN: 1470-8744 
English 
Bioreactor process changes can have a profound effect on the yield and quality of biotechnology products. Mannose-6-phosphate (M6P) glycan content and the enzymatic catalytic kinetic parameters are critical quality attributes (CQAs) of many therapeutic enzymes used to treat lysosomal storage diseases. Here, we have evaluated the effect of adding butyrate to bioreactor production cultures of human recombinant β-glucuronidase produced from CHO-K1 cells, with an emphasis on CQAs. The β-glucuronidase produced in parallel bioreactors was quantified by capillary electrophoresis, the catalytic kinetic parameters were measured using steady-state analysis, and mannose-6-phosphorylation status was assessed using an M6P-specific single chain antibody fragment. Using this approach we found that butyrate treatment increased β-glucuronidase production up to ∼3-fold without significantly affecting the catalytic properties of the enzyme. However, M6P content in β-glucuronidase was inversely correlated with the increased enzyme production induced by butyrate treatment. This assessment demonstrated that although butyrate dramatically increased β-glucuronidase production in bioreactors, it adversely impacted the mannose-6-phosphorylation of this lysosomal storage disease therapeutic enzyme. This strategy may have utility in evaluating manufacturing process changes to improve therapeutic enzyme yields and CQAs. 
IRIS
• n-Butanol
     Database searches
          Pubmed
     Database Searches - March 2014 (private)
          Pubmed - 3/2014
     Excluded (not pertinent)
          Use in sample prep or assay